New Directions in the Treatment of Patients With Chronic Myeloid Leukemia: Introduction
To access this article, please choose from the options below
Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals.
STATEMENT OF CONFLICT OF INTEREST: Dr Baccarani has received honoraria for consultancies and served on the Advisory Board and as a Speaker for Novartis Pharmaceuticals Corp.
PII: S0037-1963(09)00017-1
doi:10.1053/j.seminhematol.2009.01.006
© 2009 Published by Elsevier Inc.
